Follicular Lymphoma
From the Journals
ASCT may cure follicular lymphoma for some rituximab-naive patients
A retrospective cohort study suggests that ASCT, if performed promptly, can be curative in patients who have had an early failure of first-line...
From the Journals
Obinutuzumab-lenalidomide combo shows promise in relapsed/refractory FL
In the phase 2 GALEN study, induction with obinutuzumab and lenalidomide followed by maintenance therapy with obinutuzumab appears effective for...
News
FDA approves rituximab biosimilar for cancer, autoimmune disorders
The biosimilar is approved for certain cancers and autoimmune disorders, although, like its reference drug, it comes with a boxed warning from the...
From the Journals
CAR T-cell therapy less effective in transformed follicular lymphoma
The complete response rate and duration of response were better in patients with follicular lymphoma than in those with transformed follicular...
Conference Coverage
5F9 plus rituximab take a bite out of drug-resistant NHL
AMSTERDAM – The combination thwarts a mechanism that non-Hodgkin lymphomas use to evade immune surveillance.
Conference Coverage
R2 appears active in high-risk FL and MZL
CHICAGO – R2 produced responses in patients who were refractory to rituximab or both lenalidomide and rituximab at baseline.
Conference Coverage
Inhibitor produces high response rate in relapsed/refractory FL
CHICAGO – The PI3K-delta inhibitor ME-401, given with or without rituximab, produced an overall response rate of 80% in a phase 1b trial of...
News
FDA approves lenalidomide/rituximab for previously treated FL, MZL
The approval is based on results from the phase 3 AUGMENT trial, which compared the combination treatment with placebo in previously treated...
From the Journals
Trial follow-up spotlights survival gains in follicular lymphoma
The 13-year update to the GITMO-IIL trial showed the important role of complete remission in prolonged survival. This is the longest follow-up...
From the Journals
In situ vaccination produced responses in indolent NHL
In situ vaccination induced regression of tumors that were directly targeted, as well as tumors that were not treated, in a small study of...
Latest News
Polatuzumab outperforms pinatuzumab in non-Hodgkin lymphoma
Polatuzumab vedotin plus rituximab produced more durable responses than did pinatuzumab vedotin plus rituximab in patients with relapsed or...